Daily Medication Pearl: Upadacitinib (Rinvoq)

Article

Medication Pearl of the Day: Upadacitinib (Rinvoq)

Indication: Upadacitinib (Rinvoq)is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis.

Insight:

  • Dosing: The recommended dosage of Rinvoq is 15 mg once daily.
  • Dosage forms: Extended-release tablets 15 mg and 30 mg.
  • Adverse events: Adverse reactions (≥ 1%) were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, and acne.
  • Mechanism of action: JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
  • Manufacturer: AbbVie

Sources:

Microsoft Word - master-uspi-upadacitinib (rxabbvie.com)

rinvoq image - Google Search

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.